Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrumadenant and Zimberelimab in Advanced Dedifferentiated Liposarcoma
NCT05886634Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2023
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etrumadenant and zimberelimab in dedifferentiated liposarcoma (DDL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Response Rate at 24 weeks. Started May 2023; status: active, not recruiting.
02
Drugs
etrumadenantzimberelimab
03
Conditions
dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on NCT05886634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05886634.